Srikanth Vallurupalli

Srikanth Vallurupalli

Auto-generated profile, based on publicly available information

Srikanth Vallurupalli

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 November 2013 in Circulation
Verified
Journal Article
Closed access
ADAbhishek Deshmukh
Abhishek Deshmukh
NPNileshkumar J. Patel
Nileshkumar J. Patel
SPSadip Pant
Sadip Pant
NSNeeraj Shah
Neeraj Shah
ACAnkit Chothani
Ankit Chothani
JVJuan F. Viles-Gonzalez
Juan F. Viles-Gonzalez
Background—: Atrial fibrillation ablation has made tremendous progress with respect to innovation, efficacy, and safety. However, limited data exist regarding the burden and trends in adverse outcomes arising from this procedure. The aim of our study was to examine the frequency of adverse events attributable to atrial fibrillation (AF) ablation and the influence of operator and hospital volume on outcomes. Methods and Results—: With the use of the Nationwide Inpatient Sample, we identified AF patients treated with catheter ablation. We investigated common complications including cardiac perforation and tamponade, pneumothorax, stroke, transient ischemic attack, vascular access complications (hemorrhage/hematoma, vascular complications requiring surgical repair, and accidental arterial puncture), and in-hospital death described with AF ablation, and we defined these complications by using validated International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. An estimated 93 801 AF ablations were performed from 2000 to 2010. The overall frequency of complications was 6.29% with combined cardiac complications (2.54%) being the most frequent. Cardiac complications were followed by vascular complications (1.53%), respiratory complications (1.3%), and neurological complications (1.02%). The in-hospital mortality was 0.46%. Annual operator (<25 procedures) and hospital volume (<50 procedures) were significantly associated with adverse outcomes. There was a small (nonsignificant) rise in overall complication rates. Conclusions—: The overall complication rate was 6.29% in patients undergoing AF ablation. There was a significant association between operator and hospital volume and adverse outcomes. This suggests a need for future research into identifying the safety measures in AF ablations and instituting appropriate interventions to improve overall AF ablation outcomes.

7 June 2017 in Therapeutic Advances in Cardiovascular Disease
Verified
Journal Article
Open access
FHFuad Habash
Fuad Habash
SVSrikanth Vallurupalli
Srikanth Vallurupalli
Left ventricular thrombus (LVT) complicates both ischemic and non-ischemic cardiomyopathies and is a potential cause of thromboembolic complications such as stroke. Management of LVT in the 21st century is primarily based on studies before the widespread use of potent pharmacological and interventional therapies such as primary percutaneous coronary intervention, especially in the setting of acute myocardial infarction. Though advances in diagnostic technology have improved detection of LVT, clinicians face several uncertainties in the management of LVT in daily practice. The aim of this paper is to examine several controversies in the diagnosis and management of LVT. Prospective studies are needed to advance therapy of LVT.

26 February 2010 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
KWKenneth R Wilund
Kenneth R Wilund
ETE. J. Tomayko
E. J. Tomayko
PWP.-T. Wu
P.-T. Wu
HCH. Ryong Chung
H. Ryong Chung
SVS. Vallurupalli
S. Vallurupalli
BFB. Fernhall
B. Fernhall
Cardiovascular disease (CVD) mortality rates are greatly elevated in chronic kidney disease patients receiving maintenance haemodialysis therapy. The purpose of this study was to evaluate the efficacy of intradialytic endurance exercise training on novel risk factors that may contribute to this excessive CVD risk. Seventeen haemodialysis patients were randomized to either an intradialytic exercise training (cycling) group (EX; n = 8) or a non-exercising control group (CON; n = 9) for 4 months. At baseline and following the intervention, we measured serum parameters related to CVD risk and renal function, used echocardiography to measure variables related to cardiac structure and function and assessed physical performance by a validated shuttle walk test. Performance on the shuttle walk test increased by 17% in EX (P < 0.05), but did not change in CON. There was no change in serum lipids or inflammatory markers (C-reactive protein, interleukin-6) in either group. Serum thiobarbituric acid reactive substances, a marker of oxidative stress, were reduced by 38% in EX (P < 0.05), but did not change in CON. In addition, serum alkaline phosphatase (ALP), a putative risk factor for vascular calcification, was reduced by 27% in EX (P < 0.05), but did not change in CON. There was no change in left atrial volume, left ventricular mass or myocardial performance index in either group. However, the thickness of the epicardial fat layer was reduced by 11% in EX (P < 0.05), but did not change in CON. Furthermore, the change in physical performance was inversely correlated to the change in epicardial fat (r = -0.63; P = 0.03). These results suggest that endurance exercise training may improve CVD risk in haemodialysis patients by decreasing novel risk factors including serum oxidative stress, ALP and epicardial fat.

1 December 2014 in The American Journal of Cardiology
Verified
Journal Article
Open access
NPNaga Venkata Krishna Chand Pothineni
Naga Venkata Krishna Chand Pothineni
RDRobert Delongchamp
Robert Delongchamp
SVSrikanth Vallurupalli
Srikanth Vallurupalli
ZDZufeng Ding
Zufeng Ding
YDYao Dai
Yao Dai
JMJawahar L. Mehta
Jawahar L. Mehta
Chronic infections have been shown to enhance atherogenicity. However, the association between chronic hepatitis C (HCV) and coronary heart disease (CHD) remains controversial. We examined the risk for CHD events in patients with HCV with an emphasis on the risk of CHD events with active infection. We conducted a retrospective cohort study using the enterprise data warehouse at the University of Arkansas for Medical Sciences. HCV positive and negative patients were identified based on serology, and incident CHD events were studied. Patient characteristics at entry were compared either by the analysis of variance or F test (continuous variables) or by a chi-square test (categorical variables). The joint effect of risk factors for incident CHD was evaluated using logistic regression. A total of 8,251 HCV antibody positive, 1,434 HCV RNA positive, and 14,799 HCV negative patients were identified. Patients with HCV antibody and RNA positivity had a higher incidence of hypertension, diabetes mellitus, obesity, and chronic lung disease, but lower serum cholesterol levels compared with patients who were HCV negative (p <0.001). HCV seropositive patients had a higher incidence of CHD events compared with controls (4.9% vs 3.2%, p <0.001). In the HCV cohort, patients with detectable HCV RNA had a significantly higher incidence of CHD events compared with patients who were only HCV antibody positive with no detectable RNA (5.9% vs 4.7%, p = 0.04). In multivariate logistic regression analyses, both HCV antibody positivity (odds ratio 1.32, 95% confidence interval 1.09 to 1.60, p <0.001) and HCV RNA positivity (odds ratio 1.59, 95% confidence interval 1.13 to 2.26, p <0.001) were independent risk factors for incident CHD events. In conclusion, there is an increased incidence of CHD events in patients with HCV seropositivity and the incidence is much higher in patients with detectable HCV RNA compared with patients with remote infection who are only antibody positive. Lipid profile does not appear to be a good cardiovascular risk stratification tool in patients with HVC.

11 October 2013 in Health and Technology
Verified
Journal Article
Closed access
PDF file
SVS. Vallurupalli
S. Vallurupalli
HPH. Paydak
H. Paydak
SAS. K. Agarwal
S. K. Agarwal
MAM. Agrawal
M. Agrawal
CAC. Assad-Kottner
C. Assad-Kottner

13 January 2017 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
YDYao Dai
Yao Dai
YCYongxiang Cao
Yongxiang Cao
ZZZhigao Zhang
Zhigao Zhang
SVSrikanth Vallurupalli
Srikanth Vallurupalli
Jawahar L MehtaJawahar L Mehta
Jawahar L Mehta